Brief: Medexus Reaches 50% Enrollment In Ixinity Phase 4 Clinical Trial Targeting Label Expansion For Pediatric Hemophilia B Patients

Medexus Pharmaceuticals

16/11/2020 13:37

Nov 16 (Reuters) - Medexus Pharmaceuticals Inc  MDP.V :
    * MEDEXUS REACHES 50% ENROLLMENT IN IXINITY® PHASE 4
CLINICAL
TRIAL TARGETING LABEL EXPANSION FOR PEDIATRIC HEMOPHILIA B
PATIENTS
    * MEDEXUS PHARMACEUTICALS INC - INTENDS TO ALSO PURSUE
OUT-LICENSE
PARTNERS FOR IXINITY IN MARKETS OUTSIDE OF CANADA AND UNITED
STATES

Source text for Eikon:  ID:nGNX7P1r5n 
Further company coverage:  MDP.V 

 ((Reuters.Briefs@thomsonreuters.com;))